Clinical Trial Update: Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100 [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial is evaluating the safety and efficacy of dostarlimab plus LB-100 targeting PP2A in ovarian clear cell carcinoma, and it is currently recruitin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Clear Cell Carcinoma

Drugs mentioned

• JEMPERLI (DOSTARLIMAB)
• LB-100 (LB-100)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Ovarian Clear Cell Carcinoma | Phase 1, Phase 2 | Status: RECRUITING